Site Map | Legal Policy | Privacy Policy

 

Corporate Governance

Ligand effected the sale of all its commercial products and as of February, 2007 changed its business strategy to focus on a targeted internal research and development effort.

Title  
Annual Declaration of Compliance      
Code of Conduct and Ethics Policy      



Corporate Charters

     
Document  
Audit Committee Charter      
Compensation Committee Charter      
Nominating Committee Charter      


News

Ligand to Present at the Cowen & Company 30th Annual Healthc.......

Ligand Announces Fourth Quarter and Full Year 2009 Consolida.......

Upcoming Events

Cowen & Company 30th Annual Healthcare Conference

Investor Relations|News|Presentations & Events|SEC Documents|
Corporate Governance|Stock Information|Email Alerts
LGND - (NASDAQ)
$1.70